Shares of Tilray (TLRY), which have already garnered significant attention for their rapid ascent following the Canadian cannabis company's recent IPO, are flying even higher this morning after CEO Brendan Kennedy was a guest last night on Jim Cramer's Mad Money program on CNBC.

WANT TO BE NEXT ANHEUSER-BUSCH: "Cannabis is a substitute for prescription painkillers, prescription opioids, and so if you're an investor in a pharmaceutical company or you're a pharmaceutical company, you have to hedge the offset from cannabis substitution," Kennedy told Cramer during his appearance. He also said he thinks "all the alcohol companies need to enter this industry," adding that investing in cannabis is "a great hedge for them." Commenting on the potential for partnership interest from the likes of Anheuser-Busch InBev (BUD) and other beverage giants, Kennedy responded: "We don't want to partner with ABI. We want to build ABI. Our intent is to build a company that dominates part of this $150 billion industry. I think you'll see multiple hundred-billion-dollar companies."

PRICE ACTION: In pre-market trading, Tilray shares are up $75.02, or 48%, to $230.00.